New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins.
about
Intrabodies as neuroprotective therapeuticsGenetics and neuropathology of Huntington's diseaseMutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 miceThe structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice modelDisease-Associated Polyglutamine Stretches in Monomeric Huntingtin Adopt a Compact StructureLinear and extended: a common polyglutamine conformation recognized by the three antibodies MW1, 1C2 and 3B5H10Human mutant huntingtin disrupts vocal learning in transgenic songbirdsNormal huntingtin function: an alternative approach to Huntington's diseaseSIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivoTemporal separation of aggregation and ubiquitination during early inclusion formation in transgenic mice carrying the Huntington's disease mutationGenetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's diseaseHdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's diseaseInvolvement of C-Terminal Histidines in Soybean PM1 Protein Oligomerization and Cu2+ Binding.Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice.Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment.Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo.A fully humanized transgenic mouse model of Huntington disease.Motivational, proteostatic and transcriptional deficits precede synapse loss, gliosis and neurodegeneration in the B6.HttQ111/+ model of Huntington's disease.Quantification assays for total and polyglutamine-expanded huntingtin proteins.Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells.The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patientsProteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease.Fibril polymorphism affects immobilized non-amyloid flanking domains of huntingtin exon1 rather than its polyglutamine coreOptimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington DiseaseHuntingtin localisation studies - a technical review.TR-FRET assays of Huntingtin protein fragments reveal temperature and polyQ length-dependent conformational changes.Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicityIn-cell aggregation of a polyglutamine-containing chimera is a multistep process initiated by the flanking sequence.A linear lattice model for polyglutamine in CAG-expansion diseasesCysteine string protein (CSP) inhibition of N-type calcium channels is blocked by mutant huntingtin.Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis.Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington's diseasePolyglutamine amyloid core boundaries and flanking domain dynamics in huntingtin fragment fibrils determined by solid-state nuclear magnetic resonance.Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon agingQuantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.A compact beta model of huntingtin toxicity.Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 miceA striatal-enriched intronic GPCR modulates huntingtin levels and toxicity
P2860
Q95991578-24828707-86AC-404C-8C95-14B3D66FA96AQ95991582-DC8CC72E-EF7D-4FF4-BCE2-F27FA6DC4FB7Q95991583-92ECDA93-4B06-4701-B1F7-1B3A1B0F5255Q95991584-96D12EF3-F034-4F08-9676-6C02BF92735BQ95991585-FDCF6C26-B9A3-4FBE-AD13-C36BCF21821BQ95991586-74361D16-6ABA-4B38-8BB5-B334581CB7FDQ95991587-9D4D8EAE-937A-48E2-8FC6-66AA72316112
P1343
Q27003896-8B6EAE90-0331-493F-800D-25DA4A3BD5E1Q27023050-00572E08-1147-461C-B049-D57524490161Q27305680-28F24643-94DE-45D8-B2DB-49726AA6E807Q27644551-3BE35138-B4E3-4F92-8B18-F0E6DF52DC90Q27677065-3875713E-D074-4350-ABB6-0292DFA11635Q27684844-8629110D-C987-4037-A5B5-541A5A44858AQ28118833-00A6A469-D35F-465D-8CD9-AE03F09D2CF1Q28281904-7242EB44-724E-46FE-901D-CCF8822B11B8Q28482270-FA680BD2-61AE-4FD1-AFB6-CE3D0459CC1CQ28728849-5E1B7BF8-BE3A-43C2-BFAB-48860940C6F1Q28732195-711BC2F2-8D64-44CA-8714-EDF8BD022D79Q28743929-5C457243-2766-4DC5-A94F-CA4B7886F517Q30400862-C3AE79E6-02EE-4597-8A35-706B3F8F9425Q30437121-E0528660-6A67-4347-BA8A-0583B8853EF3Q30490726-ECD711B5-A41B-4B5F-A890-27BCE9328047Q30493159-7B36E18C-8C64-4763-BA1B-B60EE7EBF110Q30494325-93133F4B-8E21-476D-A5D3-58F09D33B3FEQ30537951-FA3F0C5F-1444-4004-B59C-65A328473FC1Q30837903-C164B295-0C8F-444C-953C-2760DDD31626Q33590805-1C3BA8DE-FBA4-4A96-8BB9-5A0488FBCB57Q33594270-3BB084EE-BDE9-469D-9A2C-8740042ACE36Q33683726-211E8AC7-8A7F-478B-B71E-C457F20E8E24Q33726473-8E888A94-B07D-4C96-8EB2-22DCF2B65491Q33761247-03F27109-33AB-4277-A9BB-8192DC8681ECQ33807006-7844BEF6-9AB1-4D42-B137-866D3980397AQ33826159-C0D9F078-A43D-4170-A097-A01C46298855Q33851150-8EB424F2-4343-4C68-8A7A-11775769F635Q33894812-4D48388B-0F67-45E7-AC2B-48DB75C1998EQ33941017-9C41498F-9ADB-40C6-9705-79C8F74FBF31Q34153913-84417C6B-8DC0-403B-A787-435D24F1152CQ34271560-DE29A555-FA8F-474D-A4BE-EC3ECF47C9C7Q34274478-5E996F2E-5758-4E40-AD6A-EC3E639DB89DQ34392516-FE67FD14-FB0A-4311-9AC0-31005B8DFC63Q34414446-38C768A3-B7CC-4E28-9796-7B46F234E6D0Q34415909-1BA4FCA7-730A-4B50-926B-C55479712E74Q34470414-F4661E45-9549-4148-A7B6-AD031A9B76DDQ34624307-1B7A94B7-15A5-4E79-AEA2-6156240A879AQ34627072-EEB5707C-2E8C-46E4-BC78-200398B5DAE7Q34692633-391F43B3-5076-4749-B5E4-9897A8C56ACBQ35214858-85B3CA25-C0D3-4B14-A54A-3213FFEA7E7E
P2860
New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
New anti-huntingtin monoclonal ...... tion and its binding proteins.
@en
New anti-huntingtin monoclonal ...... tion and its binding proteins.
@nl
type
label
New anti-huntingtin monoclonal ...... tion and its binding proteins.
@en
New anti-huntingtin monoclonal ...... tion and its binding proteins.
@nl
prefLabel
New anti-huntingtin monoclonal ...... tion and its binding proteins.
@en
New anti-huntingtin monoclonal ...... tion and its binding proteins.
@nl
P2093
P1476
New anti-huntingtin monoclonal ...... tion and its binding proteins.
@en
P2093
P304
P356
10.1016/S0361-9230(01)00599-8
P577
2001-10-01T00:00:00Z